eligibility_summary
Eligibility: Adults 18–79 with untreated Richter’s syndrome (DLBCL variant), ECOG ≤2, CD20+, adequate marrow (ANC ≥1, Hb ≥9, Plt ≥75, ≥30 if CLL marrow), CrCl ≥45, life expectancy >3 mo, effective contraception. Exclude: pregnancy/breastfeeding, prior mosunetuzumab/CD20xCD3, recent auto-SCT/CAR-T or prior allo-SCT, CNS disease, prolymphocytic transformation, serious/active infections (HIV/HBV/HCV/CAEBV/PML), autoimmune disease, severe mAb allergy, tocilizumab CI, LVEF <50, major organ/CNS disease, recent major surgery, live vaccines.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in untreated Richter’s syndrome (DLBCL-type) testing mosunetuzumab + CHOP induction (6 cycles), then mosunetuzumab monotherapy (up to 11 cycles) for non-transplant candidates. Interventions: Mosunetuzumab (IV), a CD20×CD3 bispecific T‑cell–engaging monoclonal antibody that redirects cytotoxic T cells to kill CD20+ B cells, CHOP components—cyclophosphamide (alkylating DNA crosslinker), doxorubicin (anthracycline/topoisomerase II inhibitor), vincristine (vinca alkaloid microtubule inhibitor), prednisone (glucocorticoid, lympholytic). Targets/pathways: CD20 on malignant B cells, CD3 on T cells, T‑cell activation and immune synapse formation leading to B‑cell cytotoxicity, DNA damage/apoptosis, mitotic arrest via microtubule disruption, and glucocorticoid receptor–mediated apoptosis.